Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Shimla: Pharmaceutical manufacturers in Himachal Pradesh have said the U.S. decision to impose 100% tariffs on branded and patented medicines is unlikely to cause major disruptions, as the state’s pharma sector is overwhelmingly focused on generics.
The new duty, set to take effect from October 1, will apply to imported branded and patented drugs. However, industry leaders in Himachal, home to a large concentration of pharma companies, stressed that the state’s drug makers are shielded from the impact.
“More than 95 per cent of pharmaceutical companies located in Baddi, Nalagarh, Kala Amb and Paonta Sahib are engaged in producing generic medicines,” expressed Sanjay Suri, Vice-Chairman of CII Himachal and Executive Director of Morepen Laboratories. He added that India’s role as one of the largest exporters of generics to the U.S. makes it difficult for American healthcare to risk imposing tariffs on this segment, as it would directly increase treatment costs for patients.
While industry leaders appeared confident, some struck a note of caution. Rajesh Gupta, Chairman of the Himachal Drug Manufacturers’ Association, said the exemption for generics must be clearly defined. “The distinction between generic and branded or patented drugs is not always straightforward,” he noted, adding that some companies manufacture branded medicines outside the state. According to him, clarity in the tariff notification is essential to prevent confusion.
Himachal Pradesh is among India’s leading pharma hubs, with around 580 pharmaceutical units operating in the state. Nearly 79 per cent of them are based in the Baddi-Nalagarh-Barotiwala belt of Solan district, while the remaining are concentrated in Kala Amb and Paonta Sahib in Sirmaur. Together, the state’s pharmaceutical industry boasts an estimated annual turnover of ₹40,000 crore, contributing significantly to India’s drug exports.
According to a recent media report in The Indian Express, the general consensus among industry players is that Himachal’s pharma sector will remain largely unaffected, unless the U.S. extends tariffs to generic medicines in the future.
Powered by WPeMatico
Mumbai: In a major crackdown on regulatory lapses, the Pharmacy Council of India (PCI) has prohibited 89 pharmacy colleges across Maharashtra, including 71 diploma and 18 degree institutions, from admitting students for the 2025-26 academic session.
According to a recent media report in the Times of India, the move follows three years of inspections by PCI and state technical education bodies, which exposed serious violations ranging from absence of fire and safety certificates and missing occupancy approvals to poorly equipped laboratories, infrastructure deficiencies, and unqualified faculty members. In several cases, colleges attempted to submit certificates issued by unrecognized local bodies or private agencies, which were dismissed as invalid by inspectors.
After issuing showcause notices and conducting follow-up inspections, the PCI released a circular formally declaring these colleges “Not to make admission” for the upcoming academic year. The affected institutes are spread across districts including Thane, Kolhapur, Nagpur, Nashik, and Solapur.
The council underlined that the action was essential to protect students and uphold minimum academic standards in pharmacy education. Officials noted that despite repeated warnings, many institutions failed to rectify their shortcomings.
Times of India reports that this sweeping decision is also expected to delay the state’s overall pharmacy admission process, as authorities will need to recast the seat matrix and students will be left to pick from revised options.
Powered by WPeMatico
New Delhi: US President Donald Trump’s recent decision to impose a 100 percent import tariff on branded and patented pharmaceutical products starting October 1, 2025, is unlikely to have any immediate impact on Indian pharmaceutical exports, according to key industry players.
The move, announced by Trump via his social media platform Truth Social, targets drugmakers not manufacturing in the US. He wrote, “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America.”
The US President further clarified, “IS BUILDING” will be defined as, “breaking ground” and/or “under construction.” There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”
As per PTI, Indian Pharmaceutical Alliance (IPA), which represents 23 leading Indian pharmaceutical firms, including Dr Reddy’s Laboratories, Sun Pharma, Lupin and Zydus Lifesciences, noted that Trump’s latest tariff will not have implications for the generic drugmakers.
Powered by WPeMatico
New Delhi: Reviewing the revised Phase III clinical trial protocol for booster dose administration of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in infants, the Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to Novo Medi Sciences for conducting the study as per the presented protocol.
This came after Novo Medi Sciences Private Limited submitted the amended Phase III clinical trial protocol titled, “A prospective, randomized, double-blind, multi-center, Phase III study to assess and compare the immunogenicity and safety of the 13-valent pneumococcal polysaccharide conjugate vaccine in healthy Indian subjects.”
13-valent Pneumococcal Polysaccharide Conjugate Vaccine is a vaccine that protects against invasive pneumococcal disease and pneumonia caused by 13 specific types of Streptococcus pneumoniae bacteria.
Pneumococcal conjugate vaccine is a pneumococcal vaccine made with the conjugate vaccine method and used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine.
At the recent SEC meeting on vaccines, the expert panel deliberated on the revised booster dose protocol presented by Novo Medi Sciences Private Limited.
After detailed deliberation, the committee recommended the conduct of the study as per the presented protocol.
Powered by WPeMatico
A shocking allegation has been levelled against Max Hospital in Vaishali, Ghaziabad, following the death of a one-month-old baby two days ago. The family alleged that even after the baby was declared dead at 4 PM, hospital staff continued to demand money for treatment until 6 PM.
According to the family, the hospital behaved insensitively and misled them after the child’s death. They also claimed there were discrepancies in the hospital’s paperwork and records.
For more details, check out the full story on the link mentioned below:
Max Hospital Accused of Extorting Money After Infant’s Tragic Death
Powered by WPeMatico